Form 483

B. Braun US Pharmaceutical Manufacturing, LLC Form 483, 2014-02-13

FDA issued a Form 483 to B. Braun US Pharmaceutical Manufacturing, LLC on 2014-02-13 with 6 public-safe observations.

483· Form 483 issuedHuman Drugs6 observations

B. Braun US Pharmaceutical Manufacturing, LLC · Irvine, United States · Issued February 13, 2014

Overview

  • 6 public-safe observations are available for this inspection.
  • 4 structured CFR citations are represented.
  • 3 investigators are tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

13 Feb 2014
21 CFR 211.46(b)

Equipment for Environmental Control

Cited by Jennifer M Gogley, Caryn M Mcnab, Nabeela J Chaudhry

13 Feb 2014
21 CFR 211.100(a)

Absence of Written Procedures

Cited by Jennifer M Gogley, Caryn M Mcnab, Nabeela J Chaudhry

13 Feb 2014
21 CFR 211.113(b)

Procedures for sterile drug products

Cited by Jennifer M Gogley, Caryn M Mcnab, Nabeela J Chaudhry

13 Feb 2014
21 CFR 211.113(b)

Validation lacking for sterile drug products

Cited by Jennifer M Gogley, Caryn M Mcnab, Nabeela J Chaudhry

13 Feb 2014
21 CFR 211.192

Extent of discrepancy, failure investigations

Cited by Jennifer M Gogley, Caryn M Mcnab, Nabeela J Chaudhry

Inspected site

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.113(b)Cited across public-safe Form 483 observations2x
21 CFR 211.192Cited across public-safe Form 483 observations2x
21 CFR 211.100(a)Cited across public-safe Form 483 observations1x
21 CFR 211.46(b)Cited across public-safe Form 483 observations1x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 6 observations

The source PDF and every observation in full, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere